MedTrace Logo

Predictors for Retreatement of OAB After DC Mirabegron

NCT04550702 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-09-16

No results posted yet for this study

Summary

Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB, especially for those women who need retreatment is undetermined. Thus, the aim of this study was to elucidate factors predicting retreatment of female OAB.

Conditions

  • Recurrence of Overactive Bladder Syndrome

Interventions

DRUG

Mirabegron 25mg

Mirabegron 25 mg per day

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ho-Hsiung Lin, PhD · National Taiwan University Hospital

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04550702 on ClinicalTrials.gov